Stockpolly
Search
ANTX · NASDAQ · Biotechnology

AN2 Therapeutics (ANTX)

Develops boron-chemistry medicines for hematologic disease, infectious disease, and oncology.

$6.30
Pre-market+0.36 (+6.06%)
At close$5.94(+8.39%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
18191816149127109119
Research & development1415151285837776
444433443243
General & administrative444433443243
Other expenses000020000000
Operating income−18−19−18−16−14−9−12−7−10−9−11−9
122111111111
Interest income002110111111
Other non-operating income0−2−2−1−20−1−1−11−1−1
Income before tax−17−17−17−14−13−8−11−6−9−9−10−8
Net income from continuing operations−17−17−17−14−13−8−11−6−9−9−10−8
Net income−17−17−17−14−13−8−11−6−9−9−10−8
EPS, basic−$0.65−$0.57−$0.56−$0.48−$0.43−$0.25−$0.35−$0.21−$0.31−$0.29−$0.29−$0.18
EPS, diluted−$0.65−$0.57−$0.56−$0.48−$0.43−$0.25−$0.35−$0.21−$0.31−$0.29−$0.29−$0.18
Weighted average shares, basic263030303030303030303445
Weighted average shares, diluted263030303030303030303445
EBITDA0−16−1711−120−11−6−9−10−10−8
Depreciation & amortization18002509000000
EBIT−18−17−17−14−12−9−11−6−9−10−10−8